Mubadala Investment Co PJSC Takes $2.39 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Mubadala Investment Co PJSC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 6,763 shares of the biotechnology company's stock, valued at approximately $2,386,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the fourth quarter worth about $25,000. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Natixis acquired a new stake in United Therapeutics during the fourth quarter valued at approximately $85,000. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Up 1.4%

Shares of UTHR traded up $4.24 during trading hours on Thursday, reaching $303.92. The company's stock had a trading volume of 486,726 shares, compared to its average volume of 442,352. The company has a 50 day moving average of $299.93 and a two-hundred day moving average of $340.91. The firm has a market cap of $13.71 billion, a price-to-earnings ratio of 13.35, a P/E/G ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 1-year low of $264.33 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the prior year, the business earned $6.17 EPS. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a research report on Monday, April 21st. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $392.00.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $300.93, for a total transaction of $3,310,230.00. Following the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,068,506.33. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at $929,678.52. This trade represents a 79.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 65,500 shares of company stock valued at $20,765,280. 11.90% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.